Lord, Abbett & Co
PGNX

Lord, Abbett & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Lord, Abbett & Co’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-286,361
Closed -$1.71M – 1011
2015
Q1 		$1.71M Sell
286,361
-254,172
-47% -$1.6M ﹤0.01% 869
2014
Q4 		$4.09M Buy
+540,533
New +$3.23M 0.01% 766

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Lord, Abbett & Co's PGNX Position: Q2 2015 in Review

Lord, Abbett & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2015, closing a stake of 286,361 shares — an estimated $1.71M sold.

Lord, Abbett & Co first reported a position in PGNX in Q4 2014 and held it in 2 quarters. The position peaked at $4.09M in Q4 2014. 121 funds tracked by Wall St. Rank hold PGNX as of Q2 2015.

  • Lord, Abbett & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 286,361 Progenics Pharmaceuticals Inc shares in Q2 2015, an estimated $1.71M.
  • Lord, Abbett & Co first reported a position in Progenics Pharmaceuticals Inc in Q4 2014 and held it in 2 quarters.
  • Lord, Abbett & Co's Progenics Pharmaceuticals Inc position peaked at $4.09M in Q4 2014.
  • 121 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2015.

Based on Lord, Abbett & Co's 13F filing for Q2 2015, filed 14 Aug 2015.